8-KExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Exhibit Filing (Aug 1, 2024)

Filed August 1, 2024For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on August 1, 2024, to report its financial results for the second quarter ended June 30, 2024. The key takeaway from this filing is the announcement of these financial results, which were detailed in an accompanying press release furnished as an exhibit. Investors should refer to this press release for specific financial performance metrics, revenue figures, profitability, and any updates on the company's drug pipeline and commercial progress. While the 8-K itself does not contain the detailed financial data, it serves as the official notification of the earnings release. Investors and interested parties are directed to the furnished press release (Exhibit 99.1) for a comprehensive understanding of Alnylam's performance during the second quarter. This typically includes updates on key products, research and development milestones, and forward-looking statements that are crucial for evaluating the company's current standing and future prospects.

Key Highlights

  • 1Alnylam Pharmaceuticals announced its financial results for the second quarter ended June 30, 2024, via an 8-K filing on August 1, 2024.
  • 2The 8-K filing primarily serves to furnish the press release detailing the Q2 2024 financial results.
  • 3Investors are directed to Exhibit 99.1 (the press release) for specific financial performance information.
  • 4The filing does not contain the detailed financial results within the 8-K text itself.
  • 5The information provided is furnished, not filed, for purposes of Section 18 of the Exchange Act.
  • 6The document includes the cover page interactive data file (Exhibit 104).

Frequently Asked Questions

The detailed financial results for the second quarter ended June 30, 2024, are available in the press release furnished as Exhibit 99.1 to the 8-K filing dated August 1, 2024. You should refer to that document for specific financial performance data.

This 8-K filing is significant because it officially announces Alnylam Pharmaceuticals' financial results for the second quarter of 2024. It directs investors and stakeholders to the accompanying press release for the specific details of the company's performance.

No, the 8-K filing itself does not contain the detailed Q2 earnings numbers. It states that the press release containing these details is furnished as an exhibit (Exhibit 99.1).

When information is 'furnished' under Item 2.02 of an 8-K, it means the SEC is being notified of the information (like earnings), but it is not subject to the same liability under Section 18 of the Securities Exchange Act of 1934 as if it were 'filed'. It also means it generally won't be automatically incorporated by reference into other SEC filings unless specifically stated.